ATE240342T1 - Propargylphenyl-äther a2a rezeptoragonisten - Google Patents

Propargylphenyl-äther a2a rezeptoragonisten

Info

Publication number
ATE240342T1
ATE240342T1 AT00946831T AT00946831T ATE240342T1 AT E240342 T1 ATE240342 T1 AT E240342T1 AT 00946831 T AT00946831 T AT 00946831T AT 00946831 T AT00946831 T AT 00946831T AT E240342 T1 ATE240342 T1 AT E240342T1
Authority
AT
Austria
Prior art keywords
propargylphenyl
ether
receptor agonists
agonists
receptor
Prior art date
Application number
AT00946831T
Other languages
English (en)
Inventor
Jeff A Zablocki
Elfatih O Elzein
Venkata P Palle
Gregory Nudelman
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of ATE240342T1 publication Critical patent/ATE240342T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT00946831T 1999-06-22 2000-06-21 Propargylphenyl-äther a2a rezeptoragonisten ATE240342T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/338,183 US6180615B1 (en) 1999-06-22 1999-06-22 Propargyl phenyl ether A2A receptor agonists
PCT/US2000/017001 WO2000078777A1 (en) 1999-06-22 2000-06-21 Propargyl phenyl ether a2a receptor agonists

Publications (1)

Publication Number Publication Date
ATE240342T1 true ATE240342T1 (de) 2003-05-15

Family

ID=23323754

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00946831T ATE240342T1 (de) 1999-06-22 2000-06-21 Propargylphenyl-äther a2a rezeptoragonisten

Country Status (21)

Country Link
US (1) US6180615B1 (de)
EP (1) EP1192170B1 (de)
JP (1) JP2003506459A (de)
KR (1) KR100463693B1 (de)
CN (1) CN1155608C (de)
AR (1) AR024440A1 (de)
AT (1) ATE240342T1 (de)
AU (1) AU766799B2 (de)
BR (1) BR0011850A (de)
CA (1) CA2375385C (de)
DE (1) DE60002723T2 (de)
DK (1) DK1192170T3 (de)
ES (1) ES2193975T3 (de)
IL (2) IL146931A0 (de)
MX (1) MXPA01013090A (de)
NO (1) NO322096B1 (de)
PT (1) PT1192170E (de)
TR (1) TR200103752T2 (de)
TW (1) TW558556B (de)
WO (1) WO2000078777A1 (de)
ZA (1) ZA200110553B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69932173T2 (de) * 1998-10-16 2007-06-06 Pfizer Inc. Adeninderivate
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
GB2372741A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
US20030078232A1 (en) * 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
US7262176B2 (en) 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
NZ556354A (en) 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
WO2003051881A1 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
NZ534682A (en) * 2002-02-15 2006-10-27 Cv Therapeutics Inc Polymer coating for medical devices
US6914053B2 (en) 2002-09-09 2005-07-05 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
TWI346109B (en) * 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
WO2005117910A2 (en) * 2004-05-26 2005-12-15 Inotek Pharmaceuticals Corporation Purine derivatives as adenosine a1 receptor agonists and methods of use thereof
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
MX2007003271A (es) * 2004-09-20 2007-06-05 Inotek Pharmaceuticals Corp Derivados de purina y metodos de uso de los mismos.
EA015683B1 (ru) * 2005-11-30 2011-10-31 Инотек Фармасьютикалз Корпорейшн Производные пурина и способы их применения
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
CN101516882B (zh) * 2006-07-17 2012-08-29 托维斯制药有限责任公司 A2a腺苷受体的选择性拮抗剂
US7985754B2 (en) * 2006-07-17 2011-07-26 Trovis Pharmaceuticals, Llc Selective antagonists of A2A adenosine receptors
WO2008104893A2 (en) 2007-02-28 2008-09-04 The Governors Of The University Of Alberta Compounds for preventing or treating viral infections and methods of use thereof
SG182285A1 (en) 2010-01-11 2012-08-30 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
EA201290958A1 (ru) 2010-03-26 2013-04-30 Инотек Фармасьютикалз Корпорейшн Способ снижения внутриглазного давления у людей с применением n6-циклопентиладенозина (cpa), производных cpa или их пролекарств
BR112014018413A8 (pt) 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK135130B (da) 1970-12-28 1977-03-07 Takeda Chemical Industries Ltd Analogifremgangsmåde til fremstilling af 2-substituerede adenosinderivater eller syreadditionssalte deraf.
JPS6299395A (ja) * 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
EP0444196B1 (de) * 1988-11-15 1994-06-08 Yamasa Shoyu Kabushiki Kaisha Mittel zur behandlung und prophylaxe koronarer und zerebraler ischämischer erkrankungen
ES2077070T3 (es) * 1989-06-20 1995-11-16 Yamasa Shoyu Kk Intermedio de sintesis de 2-alquiniladenosina, produccion de dicho intermedio, produccion de 2-alquiniladenosina a partir de dicho intermedio, y derivado de 2-alquiniladenosina estable.
US5189027A (en) * 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
JP2740362B2 (ja) * 1991-02-12 1998-04-15 ヤマサ醤油株式会社 安定な固体状２‐オクチニルアデノシンおよびその製造法
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US5705491A (en) * 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
US5629298A (en) * 1995-03-13 1997-05-13 University Of Massachusetts Medical Center Adenosine as a positive inotrop in the compromised heart
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
US5770716A (en) * 1997-04-10 1998-06-23 The Perkin-Elmer Corporation Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same

Also Published As

Publication number Publication date
TR200103752T2 (tr) 2002-04-22
US6180615B1 (en) 2001-01-30
ES2193975T3 (es) 2003-11-16
AR024440A1 (es) 2002-10-02
CN1155608C (zh) 2004-06-30
CA2375385C (en) 2006-02-14
DE60002723T2 (de) 2004-04-08
AU766799B2 (en) 2003-10-23
NO20016349D0 (no) 2001-12-21
CA2375385A1 (en) 2000-12-28
DE60002723D1 (en) 2003-06-18
IL146931A0 (en) 2002-08-14
EP1192170B1 (de) 2003-05-14
WO2000078777A1 (en) 2000-12-28
AU6053000A (en) 2001-01-09
DK1192170T3 (da) 2003-08-11
EP1192170A1 (de) 2002-04-03
PT1192170E (pt) 2003-09-30
NO20016349L (no) 2002-02-01
CN1358190A (zh) 2002-07-10
KR100463693B1 (ko) 2004-12-29
KR20020092158A (ko) 2002-12-11
TW558556B (en) 2003-10-21
IL146931A (en) 2006-06-11
MXPA01013090A (es) 2002-06-04
NO322096B1 (no) 2006-08-14
ZA200110553B (en) 2003-10-21
BR0011850A (pt) 2002-05-21
JP2003506459A (ja) 2003-02-18

Similar Documents

Publication Publication Date Title
ATE256141T1 (de) N-pyrazol a2a rezeptor agonisten
DE60002722D1 (de) C-pyrazol a2a rezeptor agonisten
ATE240342T1 (de) Propargylphenyl-äther a2a rezeptoragonisten
DK1019075T3 (da) Beta2-Adrenerge receptoragonister
DE60030202D1 (de) Stabhalter
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
DK2332915T3 (da) beta2-Adrenoceptoragonister
DE50015294D1 (de) Mikrotom
DE10085301T1 (de) Koaxialsteckverbinder
NO20013997D0 (no) Reseptoranalyse
ITMI20000606A0 (it) Dispositivo per il collegamento di due parti costruttive
EE200200204A (et) Asendatud bensimidasooli preparaat
NO20014010D0 (no) <beta>-alaninderivater
AU2001247227A1 (en) 2-thioether a2a receptor agonists
ID30056A (id) Agonis-agonis 5-htif
EP1189944A4 (de) G-protein gekoppelter rezeptor axor16
NO20021295L (no) Nikotinsyreacetylcholin-reseptor
ATE278659T1 (de) O-desmethylvenlafaxin-ether
PT9519T (pt) Rede informatica incorporada
FI990869A0 (fi) Olkatuki
NO992174D0 (no) S°ppelposefesteanordning
NO994855D0 (no) Baerehylster for gevaer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1192170

Country of ref document: EP